SecBot SecBot
6-K ·Filed Apr 30, 2026

EVOTF

Evotec SE
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001104659-26-052426
Notable filing: 6-K
Actionable Insight • Neutral

The cooperation agreement with MAK Capital removes near-term activist overhang and signals board stability, but no financial catalysts are provided. Monitor the June 11 AGM for any unexpected dissenting votes or strategic updates. The 'Horizon' transformation remains the key value driver — track Q1 2026 results for evidence of cost savings and revenue trajectory.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
EVOTF ▲ +27.67% at T+60d
NEUTRAL call +27.67% · α vs SPY +24.56% · entry $5.24 → $6.69
Entry = T+0 close
Apr 30, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.22%
$5.24
settled 6mo ago
T+5d
+27.67%
call +27.67% · α +25.94%
$6.69
settled 6mo ago
T+20d
+27.67%
call +27.67% · α +22.70%
$6.69
settled 5mo ago
T+60d
+27.67%
call +27.67% · α +24.56%
$6.69
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Evotec announced the nomination of Dr. Wolfgang Hofmann as an independent Supervisory Board member and entered into a cooperation agreement with activist shareholder MAK Capital, which agreed to customary voting and cooperation commitments. The AGM on June 11, 2026 will vote on board appointments and a proposed board expansion from six to seven members. This de-escalates activist pressure and supports governance stability during the ongoing 'Horizon' transformation.

Key Facts

  • Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member for election at AGM on June 11, 2026
  • Cooperation agreement reached with MAK Capital Fund LP, a key shareholder, with customary voting and cooperation commitments
  • AGM agenda includes nomination of Dieter Weinand as Chairman and proposal to expand Supervisory Board from six to seven members
  • Filing follows Evotec's 20-F (April 8, 2026) which detailed the 'Horizon' transformation, $350M Sandoz cash inflow, and $75M expected run-rate savings by 2027

Financial Impact

No financial figures disclosed in this filing. Prior 20-F reported $788.4M revenue for FY2025 and $41.1M Adjusted EBITDA.

Risk Factors

  • AGM vote outcome uncertain — any shareholder dissent could signal lingering governance concerns
  • Transformation execution risk remains despite board stability
  • Material weaknesses in internal controls over financial reporting disclosed in prior 20-F

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-052426
Document: tm2613220d1_6k.htm0001104659-26-052426
Document: 0001104659-26-052426-index-headers.html0001104659-26-052426
Document: 0001104659-26-052426-index.html0001104659-26-052426
Document: 0001104659-26-052426.txt0001104659-26-052426
5 reports for EVOTF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for EVOTF — sortable, filterable
TypeNow
May 6, 2026
24w ago
6-K
BEARISH ★ 6/10
$6.69 $6.69· 0.00%▲ +2.06%$3.33 (+50.30%)
Apr 30, 2026
25w ago
6-K
NEUTRAL ★ 4/10
$5.24 $6.69▲ +27.67%▲ +24.56%$3.33 (−36.55%)
Apr 8, 2026
28w ago
6-K
MIXED ★ 6/10
$5.24 $6.69▲ +27.67%▲ +17.21%$3.33 (−36.55%)
Apr 8, 2026
28w ago
20-F
MIXED ★ 7/10
$5.24 $6.69▲ +27.67%▲ +17.21%$3.33 (−36.55%)
Apr 7, 2026
28w ago
6-K
BULLISH ★ 7/10
$5.24 $6.69▲ +27.67%▲ +14.40%$3.33 (−36.55%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026